Invesco S&P SmallCap Health Care ETF (PSCH) Covered Calls

The Invesco S&P SmallCap Health Care ETF is an exchange-traded fund that tracks the S&P SmallCap 600 Capped Health Care Index. It provides targeted exposure to small-cap U.S. companies within the healthcare sector, including biotechnology, pharmaceuticals, and medical technology firms.

You can sell covered calls on Invesco S&P SmallCap Health Care ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PSCH (prices last updated Tue 11:15 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

The Invesco S&P SmallCap Health Care ETF (PSCH) is a sector-specific investment vehicle designed to capture the performance of small-cap healthcare companies in the United States. The fund tracks the S&P SmallCap 600® Capped Health Care Index, which is a subset of the broader S&P SmallCap 600. Its "product" is efficient, low-cost access to the most innovative and high-growth segments of the healthcare industry, where smaller firms often serve as pioneers in new medical treatments and technologies.

As of 2026, the fund’s portfolio is diversified across approximately 75 to 80 holdings, with heavy concentrations in Health Care Equipment & Supplies and Biotechnology. Key holdings include high-growth names such as Krystal Biotech, Glaukos Corp, and TransMedics Group. By focusing on the small-cap tier, PSCH offers higher volatility and potential for significant capital appreciation compared to large-cap healthcare funds, making it a favorite for tactical investors looking to play specific innovation cycles in medicine.

Competitive Landscape

PSCH operates in a specialized niche but faces competition from both broad healthcare benchmarks and other small-cap or factor-based funds. In 2026, its primary competitors include:

1. Health Care Select Sector SPDR Fund: The massive, large-cap industry benchmark. While it holds different stocks than PSCH, it competes for general healthcare sector allocations.

2. SPDR S&P Biotech ETF: A highly liquid competitor that focuses specifically on the biotechnology segment, often overlapping with the higher-risk components of PSCH.

3. Vanguard Health Care ETF: A low-cost, broad-market alternative that includes small, mid, and large-cap healthcare companies in a single portfolio.

4. iShares U.S. Medical Devices ETF: Competes for capital from investors specifically interested in the medical equipment and supplies segment of the healthcare market.

5. iShares Core S&P Small-Cap ETF: The broad small-cap benchmark that includes PSCH’s holdings as part of a much larger, diversified U.S. small-cap strategy.

Strategic Outlook and Innovation

The strategic appeal of PSCH in 2026 is its role as a "M&A Discovery" vehicle. Small-cap healthcare companies are frequently targets for acquisition by large-cap pharmaceutical giants seeking to replenish their drug pipelines. The fund’s quarterly rebalancing ensures it consistently captures the next generation of medical innovators. In 2026, the fund has benefited from the accelerating integration of AI in drug discovery and the expansion of personalized genomic medicine, sectors where small-cap firms are currently leading the charge.

Innovation for the fund is tied to the transparency and liquidity of the ETF structure. Despite the inherent volatility of small-cap biotech and med-tech, PSCH provides a diversified way to mitigate the "single-stock risk" of clinical trial failures. For sophisticated traders, PSCH is optionable, allowing for specialized strategies. While liquidity in its options can be thinner than mega-cap funds, it remains a viable tool for covered call writing to generate income from the high premiums often associated with the volatile small-cap healthcare space.

Want more examples? PSA Covered Calls | PSEC Covered Calls